Panelists for 2007 Kellogg India Business Conference
Healthcare & Biotech - Watch India! The Next Healthcare & Biotech Frontier
The convergence of talent, low costs, and strong R&D capabilities positions India as a hot destination for biotech investment. This panel will explore some of the latest trends in India's healthcare and biotech industries, including the changing landscape of patent protection and U.S. FDA approval of manufacturing facilities. From entrepreneurship at Medsphere to building the Dr. Reddy's healthcare colossus in India - this panel looks to span the gamut of opportunity in India's healthcare and biotech space. With an average life expectancy of 64 years (as opposed to 74 years in the US) and almost 4 million people living with HIV/AIDS, the Indian healthcare story is as much about fulfilling a burning need as taking advantage of a blinding opportunity.
G V Prasad leads the core team that is driving the company's growth and
transformation from a company predominantly selling API, Branded Formulations
& Generics to achieving its vision of becoming a discovery-led global
leads a section of GE's Diagnostic Imaging business focused on value products
and solutions for customers around the world.
has a strong background in strategic planning, marketing, working with
KOL's and medical societies, and e-business in both clinical and commercial
healthcare environments. He has an MBA from the Kellogg School of Northwestern
University and currently holds a faculty appointment at a major university
Khurana is a director in the Operational Strategy and Private Equity practice
at PRTM, where he leads client engagements focused on driving breakout
business performance based on operational innovation. He has more than
20 years experience in operations, consulting, government, private equity,
Sanuj K. Ravindran, M.D. is a Principal of Radius Ventures, LLC. Prior to joining Radius in February 2007, Sanuj was a Director at Burrill & Company, a San Francisco based life science venture capital firm. While with Burrill, Sanuj served as an Observer on the Boards of diaDexus and Proventys, and played an active role in several other investments including Endocyte, Neosil, Cardiokine and Arete. In addition, Sanuj led Burrill’s India group, through which he assisted a number of portfolio companies in establishing collaborations with Indian companies. Previously, Sanuj worked in the Healthcare Investment Banking Group at Merrill Lynch where he assessed financing and M&A candidates for a variety of biotechnology and pharmaceutical clients.
Amit Patel is Vice President of Corporate Development & Strategic Planning at Dr. Reddy's Laboratories, a publicly-traded (NYSE: RDY), India-based, global pharmaceutical company with $1 billion+ in annual revenue, 8000 employees, and operations in over 40 countries. Amit's primary responsibilities include chairing the Dr. Reddy's Global Business Development Council, building partnerships and alliances, pursuing mergers and acquisitions, and driving strategic growth initiatives. He is also involved in long-term strategic business planning and certain specific operational oversight within Dr. Reddy's North American operations.
Amit was previously co-founder and CEO of a healthcare software startup called MedOnTime that was later acquired by CTIS, at which he served as Vice President of Corporate Development. Earlier, Amit was a strategy consultant with Marakon Associates focusing on mergers and acquisitions. Amit received a B.S. in Economics from the Wharton School at the University of Pennsylvania, a B.A.S. in Systems Engineering from the Moore School at the University of Pennsylvania, and an MBA from Harvard Business School.